The Mammo 2026: Global Breast Cancer Virtual Congress will take place virtually on October 8–9, 2026, bringing together global perspectives on the advances, challenges, and evolving priorities shaping breast cancer care.
Organized as part of the OncoDaily O Series, Mammo 2026 is a global virtual medical congress focused on the clinical questions shaping breast cancer care in 2026. The program will cover the full breast cancer continuum, from screening and early diagnosis to precision treatment, metastatic disease, triple-negative breast cancer, survivorship, genetics, and global access to care.
OncoDaily is pleased to introduce Olema Oncology as a Bronze Sponsor of Mammo 2026: Global Breast Cancer Virtual Congress.
Olema Oncology’s support contributes to the congress and its international scientific program, which brings together breast cancer specialists to discuss advances, challenges, and evolving priorities across breast cancer prevention, diagnosis, treatment, research, and survivorship.
OncoDaily extends its appreciation to Olema Oncology for supporting Mammo 2026 and contributing to the congress’s global scientific program.
“At Olema Oncology, our work is grounded in a deep understanding of endocrine-driven cancers, and mechanisms of acquired resistance. Our goal is to translate that science into better medicines for people living with breast cancer.” – Yolande Du Toit, Vice President, Medical Affairs
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer and beyond. Olema’s work is grounded in a deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance.
Olema’s lead product candidate, palazestrant (OP-1250), is an orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) being developed for patients with ER+/HER2- advanced or metastatic breast cancer (MBC). The program is currently being evaluated in two pivotal Phase 3 studies, including as a monotherapy in the OPERA-01 trial in second/third line MBC and in combination with ribociclib, a CDK4/6 inhibitor, in the OPERA-02 trial in frontline MBC.
The company’s earlier-stage program, OP-3136, is an oral small-molecule inhibitor of lysine acetyltransferase 6 (KAT6) inhibitor being evaluated in a Phase 1 clinical study in breast cancer and other solid tumors.
Olema’s focus on breast cancer research and novel targeted therapies aligns with the scientific themes of Mammo 2026: Global Breast Cancer Virtual Congress, which will bring together international experts to discuss emerging evidence and evolving approaches to breast cancer care.
A Global Forum for the Future of Breast Cancer Care
Across two days, Mammo 2026 will explore how emerging evidence, new treatment strategies, advances in biomarkers and precision medicine, and multidisciplinary approaches are shaping breast cancer care. The congress will provide an opportunity for specialists from different disciplines and regions to share perspectives, discuss current challenges, and examine the evolving priorities of breast cancer management in 2026.
By bringing these perspectives together in one virtual forum, Mammo 2026 aims to highlight the developments shaping contemporary breast cancer practice and the questions that will continue to drive the field forward. The scientific program will be led by Giuseppe Curigliano, Antonio Marra, and Sara M. Tolaney, bringing together international expertise across breast oncology, clinical trials, translational research, and drug development.
Register and learn more about the Mammo 2026:
